



Regnan Global Equity Impact Solutions Fund

Class W

Factsheet | As at 30 June 2022

ARSN: 645 981 853

For Wholesale Investors only

About the Fund

Aims to generate long-term outperformance by investing in mission-driven companies that create value for investors by providing solutions for the growing unmet sustainability needs of society and the environment, using the United Nations Sustainable Development Goals (SDGs) as an investment lens.

Underpinned by the Regnan SDG taxonomy, the team has built a comprehensive proprietary framework to identify companies that provide solutions to the environmental and societal challenges facing the world.

A high conviction, diversified, global multi-cap portfolio with low portfolio turnover and a strong emphasis on driving impact through engagement.

Investment Objective

The Fund aims to provide a return (after fees but before costs and taxes) that exceeds the MSCI ACWI IMI Index in AUD over rolling 5 year periods.

Management Costs¹

Issuer fee ²	0.65%
-------------------------	-------


¹ You should refer to the latest Product Disclosure Statement for full details of fees and other costs you may be charged.

² This is the fee we charge for overseeing the operations of the Fund and managing the assets of the Fund. The Issuer fee is paid from the assets of the Fund and is reflected in the unit price of your investment.

Other Information

Date of inception	9 August 2021
Minimum investment	\$500,000
Buy-sell spread ³ For the Fund's current buy-sell spread information, visit www.pendalgroup.com	
Distribution frequency	Annually
APIR code	PDL7011AU

³ The buy-sell spread represents transaction costs incurred whenever you invest or withdraw funds, and may vary from time to time without notice.



The Regnan Global Equity Impact Solutions Fund has been certified by RIAA according to the strict operational and disclosure practices required under the Responsible Investment Certification Program. See www.responsibleinvestment.org for details¹.

CERTIFIED BY RIAA

¹ The Responsible Investment Certification Program does not constitute financial product advice. Neither the Certification Symbol nor RIAA recommends to any person that any financial product is a suitable investment or that returns are guaranteed. Appropriate professional advice should be sought prior to making an investment decision. RIAA does not hold an Australian Financial Services Licence.

Performance of the Fund

(%)	Total Returns		Benchmark Return
	(post-fee)	(pre-fee)	
1 month	-6.07	-6.02	-4.68
3 months	-10.78	-10.64	-8.09
6 months	-24.30	-24.06	-15.88
1 year (pa)	-	-	-
Since Inception	-26.69	-26.27	-12.20

Source: Pental as at 30 June 2022

Please note that the performance returns shown are for the period from the fund's inception and are short term in nature. Performance may therefore not reflect the longer term performance of the fund.

Historical simulated returns – Class W

Regnan Global Equity Impact Solutions Fund - Class W has been operating since August 2021. To provide a simulated longer term view of the estimated performance for Class W, we have based the estimated returns for Class W using the **Regnan Global Equity Impact Solutions Fund - Class R**, given the identical investments, and have then adjusted the returns to reflect the fee differences between Class W and Class R.

(%)	Total Returns (simulated)		Benchmark Return
	(post-fee)	(pre-fee)	
1 year (pa)	-20.38	-19.86	-8.86
Since Inception (pa)	-8.67	-8.07	3.63

Inception date: 30 November 2020

Source: Pental as at 30 June 2022

Past performance is not a reliable indicator of future performance.

About Regnan

Regnan is a responsible investment leader with a long and proud heritage providing advice and insights on important environmental, social and governance issues.

For many years our pioneering analysis has changed the way investors and businesses think about value creation and their wider responsibilities to society.

Building on that expertise, Regnan has now expanded its capabilities into responsible investment funds management, backed by the considerable resources of Pental Group.

"Regnan" is a registered trademark of Pental Group Limited (PGL) and is a standalone responsible investment business division of PGL. The Fund is issued by Pental Fund Services Limited ABN 13 161 249 332 AFS Licence 431426 (PFSL). PFSL has appointed J O Hambro Capital Management Limited to manage the assets of the Fund.

To learn more about what we do, our journey, investment process, impact investment and bespoke insights please visit regnan.com

Quarterly fund commentary

- The challenging macro environment put pressure on higher growth names, particularly in the life-sciences sector
- Companies such as Befesa, a heavy user of energy and zinc, struggled due to high commodity prices
- Earnings momentum remains encouraging, both absolute and relative, and we expect the portfolio to remain resilient.

Relative performance stabilised in the quarter, however the environment remained a challenging one, as nominal and real yields in developed markets accelerated upwards, fuelled by higher inflation expectations as energy, commodity and power prices shot up, driven in large part by the ongoing conflict in Ukraine, coupled with tight supply chains.

This environment continued to present two broad external headwinds for the portfolio. Further upwards pressure on the discount rate at which future cash flow growth is discounted. That principally affects the higher multiple growthier names in the portfolio – many of which are life-science companies that sit in the healthcare sector. Secondly, near-term margin pressure remains for some holdings where cost inflation is not instantly passed on to their customers through price increases, and these companies reside in the industrials sector.

Befesa was a key detractor over the period owing to the delayed inflationary pass-through effect. Befesa is a heavy user of energy and market concerns were magnified as the price of zinc, which drives their revenues, started to roll-off while power prices continue to soar. Happily, Befesa has protection from this to some extent, as their revenue pricing is hedged some way out. We remain of the view that the business is extremely well positioned in the rapidly expanding secondary steel and aluminium production market given their best-in-class technology and operations in the key market of China.

Over the quarter we continued to see pressure on the Brazilian education names YDUQS and Afya and the life-sciences holdings of Sartorius, Carl Zeiss, Abcam and Lonza – all largely down to rising yields rather than anything relating to their earnings fundamentals. Ansys, Tomra, and Evoqua also demonstrated strong fundamentals but pulled back having reported good numbers after what had been a very strong run in their share prices.

Encouragingly, we continue to see good earnings momentum – both in absolute and relative terms – broadly across the portfolio in spite of the headwinds mentioned above. We would expect the portfolio to remain more resilient than the broader reference index, if the market's worries continue to pivot away from inflation and the spotlight shifts towards earnings resilience in the face of a macroeconomic slowdown.

This is evidenced from some of the companies whose share price rose on the back of outstanding earnings performance during the quarter, which include Novo Nordisk, which is benefitting from off-the-chart demand for its new Wegovy obesity treatment, PTC, which raised guidance in the face of double-digit recurring revenue growth, and Alfen, whose EV charging point sales rose three-fold over 2021, driving group results which were substantially ahead of consensus.

Recently market volatility provided an opportunity to add our first new buy this year, ATS, a Canadian automation system integrator, that fits into the Circular Economy theme and has some exciting solutions to help their clients – mainly in the Healthcare and Electric Vehicle (EV) battery producer industries. ATS' focus on battery manufacturing contributes to the faster ramp-up of electric vehicles, which have at least 1/5 lower emissions than ICE, their process also results in cost reductions which is key to making EVs more affordable which ultimately drives higher adoption. We believe leading businesses such as ATS, with solutions that help their customers deal with input cost inflation, will continue to benefit in this inflationary environment and long term as resource efficiency becomes more important. There were no sales over the period.

Given the strategy's focus on mission-driven solutions providers able to grow and capture large total addressable markets, we naturally have a tilt towards growth. However, we remain vigilant in avoiding growth traps, where company growth turns negative. This is where our fundamental understanding of what we own and why, is so important. Each name in the portfolio is initiated at equal conviction, however our active approach to portfolio construction ensures we are able to shape the portfolio to reflect idiosyncratic and macro drivers.

Portfolio analysis

Top 10 Holdings (as at 30 June 2022)

Stock	Impact Solution	Absolute
Novo Nordisk A/S Class B	Today 26m of the 425m diabetic patient globally are treated with Novo Nordisk's products across the treatment cascade. As prevalence increases above 10% today (from 8% a decade prior), the diabetes patient population is expected to grow 50% to 700m by 2045. The cost of diabetes is expected to reach US\$2.5th by 2030. Novo Nordisk is also one of the few companies with obesity medicine.	6.0%
QIAGEN NV	Molecular diagnostics is the fastest-growing segment of the in-vitro diagnostics industry. It enables earlier diagnosis, allows monitoring of disease progression and better guidance for therapeutic decision-making. Qiagen's 'Sample to Insight' product philosophy is designed to facilitate uptake of molecular diagnostics. By empowering users without sophisticated molecular biology expertise to use molecular diagnostic technologies, taking them straight from the biological sample to actionable insight, Qiagen expands the adoption of molecular diagnostics, improving patient outcomes.	5.4%
PTC	Productivity growth across OECD countries was lower in the decade leading up to 2016 than it was in any other decade from 1950 (UN). While technological progress and innovation has continued, the adoption of Industry 4.0 solutions with potential to deliver significant productivity improvements remains low, particularly from small and medium sized enterprises where the costs of upgrading can be prohibitive. PTC's solutions drive digital transformation, which reduces waste and scrap in the products they design, creates efficiencies in their manufacturing processes, and optimizes the operations of their customers' processes. PTC provides global leading software solutions across the life cycle of products through computer aided design, product life cycle management, industrial IoT and augmented reality. PTC solutions increase productivity and efficiency of R&D by reducing design time by up to 30%, make manufacturing more efficient and less wasteful with up to 30% reduction in prototypes, thereby reducing costs and raw material use, and reduce the time to market by up to 57%. PTC is also improving access to Industry 4.0 solutions for smaller enterprises through the recent addition of multi-tenant SaaS based CAD (Onshape) and PLM (Arena).	5.0%
PT Bank Rakyat Indonesia	Over 200 million Indonesians live on less than \$4.50 per day, without salaries or collateral, these individuals are considered too risky for loans or live in locations too remote for the reach of traditional financial services providers. Despite this, over 56 million Micro Small Medium Enterprises (MSME) contributed greater than 50% GDP. In Indonesia in particular, only about 25% of SME's have access to lending. Bank Rakyat is helping fill this gap in the Indonesian market.	4.8%
Agilent Technologies, Inc.	The need to improvement laboratory efficiency has arguably never been greater, while the complexity of driving these efficiency improvements has never been more challenging. Agilent transitioned from simply selling instruments and consumables, to becoming a provider of integrated, interconnected solutions which it provides via Agilent Cross Labs (ACG). ACG enables laboratories, from pathology to food testing, to focus on what they do best: delivering value-additive outcomes, while Agilent helps them to optimise maximise clinical value per dollar spent.	4.7%
Evoqua Water Technologies Corp	Water pollution was estimated to represent 1.8m deaths in 2015, according to the Lancet. The solution is to implement high purity water treatment solutions and increase water re-used within industrial processes so as to reduce water withdrawals and discharges. Evoqua is the leader in sophisticated water treatment solutions and is providing service-based solutions for companies to implement better water treatment in their operations.	4.6%
Orsted	Orsted is a leader in offshore wind farm development. Electricity generation from fossil fuels is responsible for 25% of GHG emissions, 10% of fresh water withdrawals and air pollution leading to 5m preventable deaths each year. Wind energy could supply up to around 34% of global electric power demand in 2040, from 4% today. Orsted is a pioneer and the leader in offshore wind, which has the potential to help national electricity grids decarbonise at scale.	4.5%
Sartorius Stedim Biotech SA	As a leader in providing single-use (SU) equipment, Stedim is significantly driving down the cost of and improve the speed of bioprocessing, helping manufacturers make biologic drugs more affordable and help to bring new, innovative therapies to market. Its products provide an enhanced safety profile, lowering the risk of cross-contamination, as well as a significantly lower environmental footprint than their stainless steel alternatives.	4.3%
Alfen NV	Alfen supports energy transition through supplying secondary substations to grid operators to upgrade the existing grid infrastructure and with the development of smart grids, needed given the rise of decentralised renewable energy. Alfen is also building out electric vehicle charging infrastructure. Through the provision of energy storage solutions, Alfen also helps address the significant issue of intermittency that comes with renewable energy sources.	4.3%
Lonza Group AG	Biologic, large-molecule drugs, currently grow twice as fast as their small-molecule counterparts, owing to their exceptional efficacy ability to address previously untreatable conditions, such as cancers and autoimmune diseases. However, the manufacturing of biologics is complex, expensive and resource-intensive. As the world's leading contract manufacturing and development company, Lonza allows biotech companies to outsource that process manufacturing process, thereby helping them to develop more potent, complex medicines at lower cost and increased speed-to-market.	4.2%
Total		47.8%

Portfolio analysis

Country breakdown (as at 30 June 2022)

	Absolute
Austria	1.6%
Belgium	3.8%
Denmark	10.6%
France	7.6%
Germany	8.1%
Netherlands	4.3%
Norway	2.2%
Switzerland	4.2%
United Kingdom	7.1%
Japan	3.4%
Other Asia	4.8%
Canada	2.5%
USA	33.6%
Latin America	2.2%
Cash	4.0%

Source: Pandal

Sector breakdown (as at 30 June 2022)

	Absolute
Energy	0.0%
Materials	7.1%
Industrials	21.4%
Consumer Discretionary	7.8%
Consumer Staples	0.0%
Health Care	32.2%
Information Technology	12.3%
Telecommunication Services	0.0%
Utilities	4.5%
Financials ex Property Trusts	10.4%
Property Trusts	0.3%
Cash	4.0%

Source: Pandal

Active bets (as at 30 June 2022)

Top 5	Relative
NOVO NORDISK B	5.7%
QIAGEN	5.3%
PTC	5.0%
Bank Rakyat Indonesia	4.7%
AGILENT TECHNOLOGIES	4.7%

Bottom 5	Relative
APPLE	-3.5%
MICROSOFT CORP	-2.9%
Alphabet	-2.0%
AMAZON.COM	-1.5%
TESLA	-0.9%

Source: Pandal

Investment process with a purpose



Meet the Regnan Global Equity Impact Solutions team



Tim Crockford
Senior Portfolio Manager

14 years
industry experience



Mohsin Ahmad, CFA
Portfolio Manager

13 years
industry experience



Maxime Le Floch, CFA
Research Analyst

10 years
industry experience



Maxime Wille, CFA
Research Analyst

6 years
industry experience

For more information



Jeremy Dean

Head of Regnan and Responsible
Investment Distribution

Tel: 0419 460 551

Jeremy.dean@regnan.com

Risks

An investment in the Fund involves risk, including:

- **Market risk:** The risk associated with factors that can influence the direction and volatility of an overall market, as opposed to security-specific risks. These factors can affect one country or a number of countries.
- **Security specific risk:** The risk associated with an individual security.
- **International investment risk:** The risk arising from political and economic uncertainties, interest rate movements and differences in regulatory supervision associated with international investments.
- **Emerging markets risk:** The Fund may make investments that provide exposure to emerging markets. Emerging markets are generally considered riskier than developed markets due to factors such as lower liquidity, the potential for political unrest, the increased likelihood of sovereign intervention (including default and currency intervention), currency volatility and increased legal risk. Emerging market investments therefore may experience increased asset price volatility and face higher currency, default and liquidity risk.
- **Concentrated portfolio risk:** The Fund's investment strategy of seeking to generate high returns by investing in a concentrated portfolio of global shares may make the Fund more volatile than a diversified global share fund with a larger number of shares. This means there is a greater risk of negative returns, particularly over the short to medium term.
- **Currency risk:** Currency exchange rate fluctuation risk arising from investing across multiple countries.
- **Class risk:** The Fund has been established as a separate class of units in the Scheme. As the assets are held on trust for all investors, there is a risk that investors of one class, may be exposed to liabilities of another class of units and they could lose some or all of their investment in the Fund. There is also a risk that in the event of an insolvency, the assets of the Fund could be made available to creditors of another class of units of the Scheme.

Please read the Fund's Product Disclosure Statement (**PDS**) for a detailed explanation of each of these risks available on the Pental's website.

This factsheet has been prepared by Pental Fund Services Limited (**PFSL**) ABN 13 161 249 332, AFSL No 431426 and the information contained within is current as at the date of this factsheet. It is not to be published, or otherwise made available to any person other than the party to whom it is provided.

PFSL is the responsible entity of, and issuer of units in, the Fund offered in this factsheet. A product disclosure statement (**PDS**) is available for the Fund and can be obtained by calling 1300 346 821 or visiting www.pentalgroup.com. The Target Market Determination (**TMD**) for the Fund is available at www.pentalgroup.com/ddo. You should obtain and consider the PDS and TMD before deciding whether to acquire, continue to hold or dispose of units in the Fund. An investment in the Fund is subject to investment risk, including possible delays in repayment of withdrawal proceeds and loss of income and principal invested.

This factsheet is for general information purposes only, should not be considered as a comprehensive statement on any matter and should not be relied upon as such. It has been prepared without taking into account any recipient's personal objectives, financial situation or needs. Because of this, recipients should, before acting on this information, consider its appropriateness having regard to their individual objectives, financial situation and needs. This information is not to be regarded as a securities recommendation.

The information in this factsheet may contain material provided by third parties, is given in good faith and has been derived from sources believed to be accurate as at its issue date. While such material is published with necessary permission, and while all reasonable care has been taken to ensure that the information in this factsheet is complete and correct, to the maximum extent permitted by law neither PFSL nor any company in the Pental group accepts any responsibility or liability for the accuracy or completeness of this information.

Performance figures are calculated in accordance with the Financial Services Council (**FSC**) standards. Where performance returns are quoted "Post fees" then this assumes reinvestment of distributions and is calculated using exit prices which take into account management costs but not tax you may pay as an investor. Where performance returns are quoted "Pre fees and tax", they exclude the effects of management costs and any taxes. Past performance is not a reliable indicator of future performance.

If market movements, cash flows or changes in the nature of an investment (e.g. a change in credit rating) cause the Fund to exceed any of the investment ranges or limits specified, this will be rectified by PFSL as soon as reasonably practicable after becoming aware of it. If PFSL does so, it will have no other obligations in relation to these circumstances. The procedures, investment ranges, benchmarks and limits specified are accurate as at the date of this factsheet and PFSL reserves the right to vary these from time to time.